Cardurion: Bain invests $300M in Boston cardiovascular disease firm

Bain Capital is investing up to $300 million into Cardurion Pharmaceuticals Inc. from both its Bain Capital Life Sciences and Bain Capital Private Equity funds. Cardurion is a clinical-stage, 20-person company with offices in Boston and Shonan, Japan. The company is exclusively focused on cardiovascular disease, with a focus on heart failure as well as rare arrhythmia disorders. With the funding, Cardurion plans to move an enzyme inhibitor designed to treat heart failure into Phase 2 trials early...